IMGN Insider Trading
Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 5.07%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
ImmunoGen Share Price & Price History
Current Price: $0.00
Price Change: +0.30 (1.20%)
As of 02/26/2024 01:00 AM ET
ImmunoGen Insider Trading History
ImmunoGen Institutional Trading History
Data available starting January 2016
ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.
Read More on ImmunoGen
Today's Range
Now: N/A
52 Week Range
Now: N/A
Volume
40 shs
Average Volume
8,778,325 shs
Market Capitalization
$8.32 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.18
Who are the company insiders with the largest holdings of ImmunoGen?